ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company ...

Stay updated with Wall Street Breakfast! Explore tariff impacts on trade, reshoring, U.S. revenue, and latest market trends.

Shares of ProKidney surged more than 500% on Tuesday following upbeat results from its Phase 2 REGEN-007 study and a price ...

ProKidney (NASDAQ: PROK) experienced a surge of 515% during Tuesday's trading session and gained additional 8.58% after-hours ...

A mixed bag of top-line phase II data prompted stellar stock results for Prokidney Corp. and its chronic kidney disease (CKD) ...

Key PointsProKidney announced results of a Phase 2 clinical trial.The stock, which was less than $1 per share, skyrocketed on the announcement.These 10 stocks could mint the next wave of millionaires ...

ProKidney’s stock was the biggest gainer and most actively traded on Tuesday following “very intriguing” news regarding the ...

ProKidney shares soar on promising Rilparencel mid-stage data for chronic kidney disease. But PROK stock remains a high-risk ...

A mixed bag of top-line phase II data prompted stellar stock results for Prokidney Corp. and its chronic kidney disease (CKD) and diabetes therapy, rilparencel. There were statistically significant ...

Shares of ProKidney rose 558% after it reported favorable results from a study of its lead drug candidate, rilparencel, in patients with chronic kidney disease and diabetes.

ProKidney stock jumps after Phase 2 trial shows rilparencel significantly slowed kidney function decline in patients with ...

(PROK) stock soars 56% after positive mid-stage trial results for the company's lead drug rilparencel in chronic kidney ...